Recent News

• 02.02.2026 - Wave Life Sciences Announces Plans to Accelerate Regulatory Engagement with Full Control of WVE-006 for Alpha-1 Antitrypsin Deficiency
• 01.12.2026 - Wave Life Sciences Highlights Strategic Priorities for 2026 at the 44th Annual J.P. Morgan Healthcare Conference: Accelerating Development of WVE-007 (INHBE siRNA) for Obesity and Rapidly Advancing RNA Editing Portfolio
• 01.05.2026 - Wave Life Sciences to Present at 44th Annual J.P. Morgan Healthcare Conference
• 12.10.2025 - Wave Life Sciences Prices Upsized $350 Million Public Offering of Ordinary Shares and Pre-Funded Warrants

Recent Filings

• 02.02.2026 - EX-99.1 EX-99.1
• 02.02.2026 - 8-K Current report
• 01.12.2026 - 8-K Current report
• 01.12.2026 - EX-99.1 EX-99.1
• 01.06.2026 - 4 Statement of changes in beneficial ownership of securities
• 12.15.2025 - SCHEDULE 13D/A General Statement of Acquisition of Beneficial Ownership
• 12.15.2025 - 4 Statement of changes in beneficial ownership of securities
• 12.11.2025 - 424B5 Prospectus [Rule 424(b)(5)]
• 12.11.2025 - EX-99.1 EX-99.1
• 12.11.2025 - 8-K Current report